The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. This assay has become the main endpoint neutralization assay used for the assessment of pre-clinical and clinical trial samples by a growing number of laboratories worldwide. Here we present the results of the formal optimization and validation of the TZM-bl assay, performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines. The assay was evaluated for specificity, accuracy, precision, limits of detection and quantitation, linearity, range and robustness. The validated manual TZM-bl assay was also adapted, optimized and qualified to an automated 384-well format.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040342 | PMC |
| http://dx.doi.org/10.1016/j.jim.2013.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Induction of Tier 2 HIV-Neutralizing IgA Antibodies in Rhesus Macaques Vaccinated with BG505.664 SOSIP.
Vaccines (Basel)
December 2024
Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Background: A goal of mucosal human immunodeficiency virus type 1 (HIV-1) vaccines is to generate mucosal plasma cells producing polymeric IgA (pIgA)-neutralizing antibodies at sites of viral entry. However, vaccine immunogens capable of eliciting IgA neutralizing antibodies (nAbs) that recognize tier 2 viral isolates have not yet been identified.
Methods: To determine if stabilized native-like HIV-1 envelope (Env) trimers could generate IgA nAbs, we purified total IgA and IgG from the banked sera of six rhesus macaques that had been found in a previous study to develop serum nAbs after subcutaneous immunization with BG505.
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Lancet HIV
January 2025
Duke University Medical Center, Durham, NC, USA.
Background: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.
View Article and Find Full Text PDFMitochondrial resilience and antioxidant defence against HIV-1: unveiling the power of extracts and Shatavarin IV.
Front Microbiol
October 2024
Division of Virology, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.
Article Synopsis
- AR, an Ayurvedic botanical, was studied for its effects on HIV-1 replication and its ability to reduce mitochondrial dysfunction during infection.
- Both AR root extracts and its main active compound, Shatavarin IV, showed non-toxic, dose-dependent inhibition of HIV-1 in laboratory tests, particularly effective against certain viral subtypes.
- Shatavarin IV interacted with key enzymes involved in HIV-1 replication, suggesting its potential as a therapeutic agent, while also helping to alleviate mitochondrial damage caused by the virus.
Transmission of highly virulent CXCR4 tropic HIV-1 through the mucosal route in an individual with a wild-type CCR5 genotype.
EBioMedicine
November 2024
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Article Synopsis
- Nearly all transmitted HIV-1 cases are CCR5 (R5)-tropic, but this research identifies a case of CXCR4 (X4)-tropic HIV-1 in a participant from the RV217 cohort, highlighting its transmissibility.
- The X4 HIV-1 caused faster depletion of CD4 T cells compared to R5 infections, affecting naive and central memory CD4 subsets more severely, while showing resistance to certain broadly neutralizing antibodies (bNAbs).
- This study suggests that X4-tropic HIV-1 can be transmitted among individuals with a normal CCR5 gene, indicating that the specific tropism of HIV-1 could influence its transmission potential and
Exploring American Elderberry Compounds for Antioxidant, Antiviral, and Antibacterial Properties Through High-Throughput Screening Assays Combined with Untargeted Metabolomics.
bioRxiv
September 2024
Center for Agroforestry, University of Missouri, Columbia, MO, U.S.A.
American elderberry ( subsp. ) is a rapidly emerging new perennial crop for Missouri, recognized for its high level of bioactive compounds with significant health benefits, including antibacterial, antiviral, and antioxidant properties. A high-throughput screening assay combined with untargeted metabolomics analysis was utilized on American elderberry juice from 21 genotypes to explore and characterize these bioactive compounds.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!